Back to resultsLong-term Follow-up After Stroke (The LAST-long Trial) (LAST-long)
Primary Purpose
Stroke
Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Intervention
Control
Sponsored by
About this trial
This is an interventional supportive care trial for Stroke focused on measuring Rehabilitation, Cognition, Physical Fitness, Case Managers, Secondary prevention
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage)
- mRS < 5
- Living in Trondheim, Skedsmo or Lørenskog municipality
- Less than 10 points on Short Physical Performance Battery (SPPB) OR less than 26 points on Montreal Cognitive Assessment (MoCA) OR more than 27 points on the 7 item version of the Fatigue Severity Scale (FSS-7) OR more than 7 points on the depression or anxiety items on Hospital Anxiety and Depression Scale (HADS) OR reduced hand function (i.e. fails on Motor Assessment Scale - Advanced arm- and hand function, item 3)
- Able to understand Norwegian
- Able and willing to sign informed consent.
Exclusion Criteria:
- Life expectancy < 12 months
- Other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).
Sites / Locations
- Akershus University HospitalRecruiting
- Vestre Viken Bærum HospitalRecruiting
- St Olavs Hospital Stroke UnitRecruiting
- Ålesund HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intervention
Control
Arm Description
Regular follow up by a community based stroke coordinator
Usual care
Outcomes
Primary Outcome Measures
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Secondary Outcome Measures
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Barthel Index
ADL function
Barthel Index
ADL function
Barthel Index
ADL function
Nottingham IADL
Extended activities of daily life (ADL) function
Nottingham IADL
Extended activities of daily life (ADL) function
Nottingham IADL
Extended activities of daily life (ADL) function
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Short Physical Performance Battery (SPPB)
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Short Physical Performance Battery (SPPB)
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Short Physical Performance Battery
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Dynamometer
Grip strength
Dynamometer
Grip strength
Dynamometer
Grip strength
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
ActivPAL
Activity monitoring across seven days
ActivPAL
Activity monitoring across seven days
ActivPAL
Activity monitoring across seven days
Montreal Cognitive Assessment
Cognitive function
Montreal Cognitive Assessment
Cognitive function
Montreal Cognitive Assessment
Cognitive function
Trail making test A and B
Executive function
Trail making test A and B
Executive function
Trail making test A and B
Executive function
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Total cholesterol
The level of total cholesterol will be measured by a blood test
Total cholesterol
The level of total cholesterol will be measured by a blood test
Total cholesterol
The level of total cholesterol will be measured by a blood test
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Hemoglobin
The hemoglobin level will be measured by a blood test
Hemoglobin
The hemoglobin level will be measured by a blood test
Hemoglobin
The hemoglobin level will be measured by a blood test
Creatinine
The creatinine level will be measured by a blood test
Creatinine
The creatinine level will be measured by a blood test
Creatinine
The creatinine level will be measured by a blood test
C-reactive protein (CRP)
The CRP level will be measured by a blood test
C-reactive protein (CRP)
The CRP level will be measured by a blood test
C-reactive protein (CRP)
The CRP level will be measured by a blood test
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Health care costs
Data from available registries will be used to estimate costs in Euro
Adherence to the intervention
Number of attended meetings with the stroke coordinator
Exercise Adherence Rating Scale
Exercise Adherence Rating Scale measures the level of adherence to the recommended and agreed activities and the reasons for not adhering.
Patient diaries
Adherence to the recommended and agreed activities
Adverse events
Adverse events will be registered to assess the safety of the intervention.
Full Information
NCT ID
NCT03859063
First Posted
February 11, 2019
Last Updated
October 5, 2023
Sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital, University Hospital, Akershus, Asker & Baerum Hospital, Alesund Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03859063
Brief Title
Long-term Follow-up After Stroke (The LAST-long Trial)
Acronym
LAST-long
Official Title
A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 11, 2019 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital, University Hospital, Akershus, Asker & Baerum Hospital, Alesund Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.
Detailed Description
In a clinical randomized controlled trial, participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months.
The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
Those randomized to the control group will receive standard care.
Patients living in the municipalities of Trondheim, Lørenskog and Skedsmo admitted to Akershus University Hospital or St. Olavs University Hospital will be included at the outpatients clinic 3 months after the stroke.
All patients will be re-assessed at 6, 12 and 18 months after inclusion. Primary outcome will be modified Rankin Scale at 18 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
Rehabilitation, Cognition, Physical Fitness, Case Managers, Secondary prevention
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A two armed parallel group randomized controlled trial
Masking
InvestigatorOutcomes Assessor
Masking Description
Single-blinded. The investigator and outcomes assessor will be blinded to group allocation.
Allocation
Randomized
Enrollment
301 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Regular follow up by a community based stroke coordinator
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Usual care
Intervention Type
Behavioral
Intervention Name(s)
Intervention
Intervention Description
Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
Intervention Type
Behavioral
Intervention Name(s)
Control
Other Intervention Name(s)
Usual care
Intervention Description
Community based follow-up as usual
Primary Outcome Measure Information:
Title
Modified Rankin Scale (mRS)
Description
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Modified Rankin Scale (mRS)
Description
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Time Frame
6 months
Title
Modified Rankin Scale (mRS)
Description
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Time Frame
12 months
Title
Barthel Index
Description
ADL function
Time Frame
6 months
Title
Barthel Index
Description
ADL function
Time Frame
12 months
Title
Barthel Index
Description
ADL function
Time Frame
18 months
Title
Nottingham IADL
Description
Extended activities of daily life (ADL) function
Time Frame
6 months
Title
Nottingham IADL
Description
Extended activities of daily life (ADL) function
Time Frame
12 months
Title
Nottingham IADL
Description
Extended activities of daily life (ADL) function
Time Frame
18 months
Title
Stroke Impact Scale (SIS)
Description
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Time Frame
6 months
Title
Stroke Impact Scale (SIS)
Description
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Time Frame
12 months
Title
Stroke Impact Scale (SIS)
Description
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Time Frame
18 months
Title
The 5-level EQ-5D version (EQ-5D-5L)
Description
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Time Frame
6 months
Title
The 5-level EQ-5D version (EQ-5D-5L)
Description
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Time Frame
12 months
Title
The 5-level EQ-5D version (EQ-5D-5L)
Description
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Time Frame
18 months
Title
Short Physical Performance Battery (SPPB)
Description
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Time Frame
6 months
Title
Short Physical Performance Battery (SPPB)
Description
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Time Frame
12 months
Title
Short Physical Performance Battery
Description
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Time Frame
18 months
Title
Dynamometer
Description
Grip strength
Time Frame
6 months
Title
Dynamometer
Description
Grip strength
Time Frame
12 months
Title
Dynamometer
Description
Grip strength
Time Frame
18 months
Title
6 Minute Walk Test
Description
Endurance. Walking distance during 6 minutes.
Time Frame
6 months
Title
6 Minute Walk Test
Description
Endurance. Walking distance during 6 minutes.
Time Frame
12 months
Title
6 Minute Walk Test
Description
Endurance. Walking distance during 6 minutes.
Time Frame
18 months
Title
ActivPAL
Description
Activity monitoring across seven days
Time Frame
6 months
Title
ActivPAL
Description
Activity monitoring across seven days
Time Frame
12 months
Title
ActivPAL
Description
Activity monitoring across seven days
Time Frame
18 months
Title
Montreal Cognitive Assessment
Description
Cognitive function
Time Frame
6 months
Title
Montreal Cognitive Assessment
Description
Cognitive function
Time Frame
12 months
Title
Montreal Cognitive Assessment
Description
Cognitive function
Time Frame
18 months
Title
Trail making test A and B
Description
Executive function
Time Frame
6 months
Title
Trail making test A and B
Description
Executive function
Time Frame
12 months
Title
Trail making test A and B
Description
Executive function
Time Frame
18 months
Title
Global Deterioration Scale (GDS)
Description
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Time Frame
6 months
Title
Global Deterioration Scale (GDS)
Description
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Time Frame
12 months
Title
Global Deterioration Scale (GDS)
Description
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Time Frame
18 months
Title
Hospital Anxiety and Depression Scale (HADS)
Description
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time Frame
6 months
Title
Hospital Anxiety and Depression Scale (HADS)
Description
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time Frame
12 months
Title
Hospital Anxiety and Depression Scale (HADS)
Description
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time Frame
18 months
Title
Fatigue Severity Scale (FSS-7)
Description
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Time Frame
6 months
Title
Fatigue Severity Scale (FSS-7)
Description
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Time Frame
12 months
Title
Fatigue Severity Scale (FSS-7)
Description
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Time Frame
18 months
Title
Part 2 of the Client Service Receipt Inventory
Description
A measure of caregivers work participation and absenteeism
Time Frame
6 months
Title
Part 2 of the Client Service Receipt Inventory
Description
A measure of caregivers work participation and absenteeism
Time Frame
12 months
Title
Part 2 of the Client Service Receipt Inventory
Description
A measure of caregivers work participation and absenteeism
Time Frame
18 months
Title
Total cholesterol
Description
The level of total cholesterol will be measured by a blood test
Time Frame
6 months
Title
Total cholesterol
Description
The level of total cholesterol will be measured by a blood test
Time Frame
12 months
Title
Total cholesterol
Description
The level of total cholesterol will be measured by a blood test
Time Frame
18 months
Title
Low Density Lipoprotein (LDL)
Description
The LDL level will be measured by a blood test
Time Frame
6 months
Title
Low Density Lipoprotein (LDL)
Description
The LDL level will be measured by a blood test
Time Frame
12 months
Title
Low Density Lipoprotein (LDL)
Description
The LDL level will be measured by a blood test
Time Frame
18 months
Title
High Density Lipoprotein (HDL)
Description
The HDL level will be measured by a blood test
Time Frame
6 months
Title
High Density Lipoprotein (HDL)
Description
The HDL level will be measured by a blood test
Time Frame
12 months
Title
High Density Lipoprotein (HDL)
Description
The HDL level will be measured by a blood test
Time Frame
18 months
Title
Longterm blood sugar (HbA1c)
Description
The HbA1c level will be measured by a blood test
Time Frame
6 months
Title
Longterm blood sugar (HbA1c)
Description
The HbA1c level will be measured by a blood test
Time Frame
12 months
Title
Longterm blood sugar (HbA1c)
Description
The HbA1c level will be measured by a blood test
Time Frame
18 months
Title
Hemoglobin
Description
The hemoglobin level will be measured by a blood test
Time Frame
6 months
Title
Hemoglobin
Description
The hemoglobin level will be measured by a blood test
Time Frame
12 months
Title
Hemoglobin
Description
The hemoglobin level will be measured by a blood test
Time Frame
18 months
Title
Creatinine
Description
The creatinine level will be measured by a blood test
Time Frame
6 months
Title
Creatinine
Description
The creatinine level will be measured by a blood test
Time Frame
12 months
Title
Creatinine
Description
The creatinine level will be measured by a blood test
Time Frame
18 months
Title
C-reactive protein (CRP)
Description
The CRP level will be measured by a blood test
Time Frame
6 months
Title
C-reactive protein (CRP)
Description
The CRP level will be measured by a blood test
Time Frame
12 months
Title
C-reactive protein (CRP)
Description
The CRP level will be measured by a blood test
Time Frame
18 months
Title
Blood pressure
Description
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Time Frame
6 months
Title
Blood pressure
Description
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Time Frame
12 months
Title
Blood pressure
Description
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Time Frame
18 months
Title
Body mass index (BMI)
Description
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Time Frame
6 months
Title
Body mass index (BMI)
Description
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Time Frame
12 months
Title
Body mass index (BMI)
Description
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Time Frame
18 months
Title
Health care costs
Description
Data from available registries will be used to estimate costs in Euro
Time Frame
18 months
Title
Adherence to the intervention
Description
Number of attended meetings with the stroke coordinator
Time Frame
18 months
Title
Exercise Adherence Rating Scale
Description
Exercise Adherence Rating Scale measures the level of adherence to the recommended and agreed activities and the reasons for not adhering.
Time Frame
18 months
Title
Patient diaries
Description
Adherence to the recommended and agreed activities
Time Frame
18 months
Title
Adverse events
Description
Adverse events will be registered to assess the safety of the intervention.
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage)
mRS < 5
Living in Trondheim, Skedsmo or Lørenskog municipality
Less than 10 points on Short Physical Performance Battery (SPPB) OR less than 26 points on Montreal Cognitive Assessment (MoCA) OR more than 27 points on the 7 item version of the Fatigue Severity Scale (FSS-7) OR more than 7 points on the depression or anxiety items on Hospital Anxiety and Depression Scale (HADS) OR reduced hand function (i.e. fails on Motor Assessment Scale - Advanced arm- and hand function, item 3)
Able to understand Norwegian
Able and willing to sign informed consent.
Exclusion Criteria:
Life expectancy < 12 months
Other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Torunn Askim, phd prof
Phone
+47 73412556
Email
torunn.askim@ntnu.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jorunn Helbostad, phd prof
Organizational Affiliation
Norwegian University for Science and Technology
Official's Role
Study Director
Facility Information:
Facility Name
Akershus University Hospital
City
Lørenskog
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bente Thommessen, PhD
Email
Bente.Thommessen@ahus.no
First Name & Middle Initial & Last Name & Degree
Elin Bergh, MD
Email
Elin.Josefina.Bergh@ahus.no
Facility Name
Vestre Viken Bærum Hospital
City
Sandvika
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Håkon Hile-Hansen
Email
HAAIHL@vestreviken.no
Facility Name
St Olavs Hospital Stroke Unit
City
Trondheim
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Torunn Askim, phd prof
Email
torunn.askim@ntnu.no
First Name & Middle Initial & Last Name & Degree
Anne Hokstad, phd
Email
anne.hokstad@ntnu.no
Facility Name
Ålesund Hospital
City
Ålesund
ZIP/Postal Code
6017
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Møre and Romsdal H Trust
First Name & Middle Initial & Last Name & Degree
Yngve M Seljeseth
Email
Yngve.Muller.Seljeseth@helse-mr.no
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35349186
Citation
Gibson E, Koh CL, Eames S, Bennett S, Scott AM, Hoffmann TC. Occupational therapy for cognitive impairment in stroke patients. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.
Results Reference
derived
Learn more about this trial
Long-term Follow-up After Stroke (The LAST-long Trial)
We'll reach out to this number within 24 hrs